Stock Groups

HCW Biologics Stock Soars after Receiving FDA Clearance for Phase 1 Trial -Breaking

by Mike Robinson

[ad_1]

© Reuters.

Sam Boughedda

Investing.com — HCW Biologics Inc (NASDAQ:) has been given a boost after the Food and Drug Administration gave the company clearance to proceed with a Phase 1b Clinical Trial for its pancreatic cancer drug.

Called HCW9218, the drug  is the company’s lead candidate, which is why HCW’s share price has seen a significant reaction to the news, surging to a high of $7.05 following Wednesday’s close at $2.92.

Hing C.Wong is the founder and CEO at HCW Biologics. He stated: “The FDA has given clearance for us to start our first in-human study for HCW9218 pancreatic cancer treatment. This milestone marks an important step for HCW Biologics as well as our efforts to develop potentially revolutionary immunotherapy treatments for other diseases and cancers.

The company has announced Lisa Giles, Gary Winer and other new board members on Wednesday. 

Disclaimer Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this website’s data including quotes, charts, or buy/sell signal information. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.



[ad_2]